MHLW’s Interim Report On Implementation Of Rare Disease Research
This article was originally published in PharmAsia News
The Health Sciences Council of Japan’s Ministry of Health, Labor, and Welfare has compiled an interim report on new hospitals and facilities used by pharmaceutical companies in developing drug treatments for incurable diseases.
You may also be interested in...
FDA seems poised to approve the drug for the orphan eye disease called TED, but remains concerned about labeling for some adverse events.
The apparently first-ever FDA press release for an advertising warning letter underscores importance of opioid issues – and the agency’s changing approach to media relations in general. FDA objects to Alkermes journal ad that excludes risk information about its opioid dependence treatment drug.